Websites advertise non-existent 'Trumpcare' health plans

Amy Baxter | | Health Exec | Policy & Regulations

Trumpcare healthcare plans pop up in online search results for health insurance, but there’s one problem: Trumpcare plans aren’t actually real.

That’s according to Axios, which reported that bare-bones health plans are being touted as Trumpcare plans online, muddying the waters for those seeking health insurance coverage on the individual market. The plans are advertised for as low as $59 per month.

An Axios reporter who dove into the plans discovered many were actually short-term limited-duration health plans that do not offer comprehensive coverage and do not have to follow Obamacare requirements, including essential health benefits.

The Trump administration expanded short-term health plans in 2018, allowing people to use them for a maximum of three years instead of three months. The plans, which were originally intended to cover people in between comprehensive coverage, have been criticized as junk insurance.

See the full story below:

Ads for "Trumpcare," which doesn't exist, are everywhere

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.